Since there are little data available to date on the mucosal immune response following booster vaccination, essentially referring to BNT162b2 (Pfizer-BioNTech) booster dose administration, the aim of this study was to characterize salivary IgA mucosal immunity in response to different combinations of COVID-19 vaccine formulations. The gene discussed is CD79A; the disease is COVID-19.